53 results about "[Candida] conglobata" patented technology

The invention relates to topical formulations and methods of use of flucytosine which demonstrate a clear advantage over currently available therapeutic regimens for the treatment and maintenance of fungal infections, particularly vulvovaginal candidiasis. The invention provides compositions which solve the long-standing need for antimicrobial agents which treat effectively resistant strains of Candida spp., especially C. albicans, C. glabrata, and C. tropicalis, and which pose limited risk of side effects, adverse reactions, or the development of resistant pathogens. The invention provides novel topical formulations of flucytosine designed to allow the active drug to act at the local application area, but which inhibit or moderate transdermal or transmucosal absorption of the drug, thus limiting systemic exposure.

The invention provides pubes-cleaning disinfection nursing liquid used for the pudendum and the vagina of a human body, which consists of 'chlorhexidine acetate (or chlorhexidine gluconate), borneol and osthole' added with a proper amount of synergist and the balance of distilled water, wherein the pH value is adjusted to be 4 to 5 by a pH balance factor. The product can kill pathogenic bacteria of HIV, neisseria gonorrhoeae, staphylococcus aureus, escherichia coli, candida albicans and the like and other viruses in one minutes so as to block cross infections of various infectious diseases, eliminate smells and relieve itching.

The present disclosure relates in part to extracts of cranberry (Vaccinium macrocarpon) comprising an enriched amount of certain compounds having anti-infective activity, e.g. antibacterial and/or antifungal activity, e.g. activity against C. albicans. Another aspect of the disclosure relates to combined cranberry and cinnamon extracts. In certain embodiments, these combined extracts have been optimized to control urinary tract infections caused by E. coli, S. aureus and C. albicans. Certain embodiments of the extract are enriched in bioactive compounds that have been shown to inhibit C. albicans adhesion and/or biofilm formation and its growth in vitro. In another aspect of the disclosure, the extracts are enriched in bioactives derived from cranberry and cinnamon that have been shown to inhibit the attachment and the growth of common urinary tract pathogens like E. coli, S. aureus and C. albicans.

The invention relates to a Chinese medicinal extractum and an extraction process thereof. The Chinese medicinal extractum comprises the following components: lightyellow sophora root, glabrous greenbrier rhizome and cortex dictamni, wherein the mass ratio of the three components is 1-6:1-6:1-3. The preparation process is characterized by comprising the following steps: grinding the raw materials of lightyellow sophora root, glabrous greenbrier rhizome and cortex dictamni into fine powders; putting the fine powders into 50 to 95 percent ethanol to carry out reflux extraction for 1 to 3 hours at a temperature of between 75 and 95 DEG C, wherein the ratio of the raw materials to ethanol is 1:10-20 (weight/volume); carrying out filtration on the obtained product after extraction; putting the powders obtained by filtration into the ethanol repeatedly to extract 1 to 2 times again; after mixing the medical solution extracted repeatedly, carrying out pressure reduction and concentration on the mixture, and carrying out low-temperature vacuum drying on the obtained product to obtain the Chinese medicinal extractum. The process is simple, has short time consumption and high yield, and is convenient for the industrial production. The yield of the Chinese medicinal extractum is over 26 percent. Bacteriostasis test shows that the MIC value of the Chinese medicinal extractum to Candida albicans is 0.195mg/ml, the MBC value of the Chinese medicinal extractum to Candida albicans is 0.78mg/ml, and the Chinese medicinal extractum has obvious effect of inhibiting and killing Candida albicans.

The invention discloses application of streptococcus sanguis protein to preparation of drugs inhibiting candida albicans and relates to application of streptococcus sanguis protein on drugs. The problems that azole type and polyenoid type chemical synthesis drugs are large in toxic and side effects in treatment of candidal infection and drug-resistant strain bacteria can be generated easily are solved. The streptococcus sanguis mixed protein is used for preparing the drugs inhibiting the candida albicans. The streptococcus sanguis protein makes the cell morphology of the candida albicans change and the membrane permeability increased, the adhesive effect and the gemmation of the candida albicans are inhibited, and generation of hyphae is interdicted. According to the application, streptococcus sanguis extracts are used for funguses antagonism, and it is verified that the streptococcus sanguis extracts have a high inhibiting effect on funguses.

The invention relates to application of betulinic acid and pharmaceutically acceptable salts thereof in preparation of drugs for resisting fungus biofilms. The invention provides a method for effectively resisting candida albicans biofilms. The adopted compound betulinic acid has effects of inhibiting the growth of candida albicans biofilms or inhibiting mature biofilms at a low concentration, and the minimal effective concentration of the compound betulinic acid is only 2.0 micron mol/L. The application of betulinic acid in preparation of drugs for resisting fungus biofilms, provided by the invention, not only provides a new application for betulinic acid, but also provides an effective drug for clinically inhibiting formation of fungus biofilms or damaging mature fungus biofilms.

The invention provides 2,5-diketopiperazine dipeptide (I) derived from lysobacter enzymogenes as well as a preparation method and an application thereof and an endophytic bacterium producing 2,5-diketopiperazine dipeptide, namely lysobacter enzymogenes R-2-1. 2,5-diketopiperazine dipeptide (I) has the main beneficial effects that (1) lysobacter enzymogenes R-2-1 producing 2,5-diketopiperazine dipeptide (I) is provided and is the first lysobacter enzymogenes produced in the strain; (2) 2,5-diketopiperazine dipeptide (I) has strong inhabiting effects on aspergillus flavus and candida albicans, can serve as a novel bactericide and can be further used for preparing medicament for treating relevant diseases caused by aspergillus flavus or candida albicans; (3) 2,5-diketopiperazine dipeptide (I) is produced by liquid fermentation of lysobacter enzymogenes R-2-1 and has the advantages of simple and convenient operation process, short period, low cost and ensured origin; (4) 2,5-diketopiperazine dipeptide (I) is synthesized by a biological method and does not pollute the environment.

The present invention relates to ophthalmic compositions comprising a pH between about 6 and about 8 and about 50 to about 1000 ppm hydrogen peroxide and at least one phosphate buffer. The ophthalmic compositions of the present invention display improved antifungal efficacy against fungi, including candidas albicans and fusarium solani.

Propionic acid is used to curb the growth of Candida albicans, Aspergillus niger, Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus in personal care products. Carnosic acid may be substituted for some of the propionic acid to provide a synergistic combination.

The invention discloses oral disinfecting liquid for nursing. The disinfecting liquid consists of the following ingredients in parts by weight: 11-16 parts of ethanol, 5-11 parts of sorbitol, 6-10 parts of tea polyphenol, 7-9 parts of glycyrrhizin, 1-2 parts of rhizoma smilacis glabrae, 1-2 parts of fructus cnidii, 1-2 parts of honeysuckle, 3-5 parts of radix sophorae flavescentis, 3-5 parts of cortex phellodendri, 3-5 parts of radix gentianae and 100-150 parts of de-ionized water. Compared with the prior art, the disinfecting liquid disclosed by the invention has the following beneficial effects: (1) the disinfecting liquid is significant in sterilizing and disinfecting effects on escherichia coli, staphylococcus aureus, candida albicans and the like, and a killing rate within 1min reaches 100%; (2) the disinfecting liquid, which is subject to a traditional Chinese medicine formula, is non-toxic, non-irritant, anti-corrosive and faint in fragrance; and (3) the disinfecting liquid is broad in application scope and is suitable for various fields; and the disinfecting liquid is suitable for disinfecting and sterilizing oral cavities of people at all ages, in particular removing bad breath in oral cavity with the most ideal effect.

The invention provides the use of an eurycoma longifolia extract for treating bacterial infection and dermatitis. The eurycoma longifolia extract comprises scopoletin, 9-methoxy-canthium dicoccum-6-ketone, eurylene and the like. Bacteria comprise escherichia coli, staphylococcus aureus, pseudomonas aeruginosa, streptococcus pyogenes, candida albicans, klebsiella pneumoniae and pseudomonas aeruginosa.

The invention discloses an application of an indolyl diketopiperazine compound in preparation of antifungal medicines. According to the application, the discovered compound, i.e., 1,2,3,4-tetrahydro-2-methyl-3-methylene-1,4-dioxopyrazino[1,2-a]indole has a very high inhibiting effect on Candida albicans, Trichoderma viride, Aspergillus niger and Aspergillus flavus, so that the compound, i.e., 1,2,3,4-tetrahydro-2-methyl-3-methylene-1,4-dioxopyrazino[1,2-a]indole has very good antifungal activity and has a good application development prospect. Therefore, the invention provides candidate drugs for researching and developing novel antifungal medicines and provides a scientific basis for developing and utilizing marine fungus derived natural active substances.

The invention relates to an application of an AHAS (acetohydroxyacid synthase) inhibitor in preparing a medical antifungal medicament, and mainly relates to an application of sulfonylurea compounds (chlorimuron ethyl, ethoxysulfuron, bensulfuron methyl and pyrazosulfuron ethyl) in preparing medicaments capable of resisting Candida albicans, Cryptococcus neoformans, Saccharomyces cerevisiae, Candida parapsilopis and Candida glabrata and the like. The compounds can be used for intensely restraining the AHAS from fungal, and has a higher restraint effect on multiple types of fungi capable of causing infection at the cellular level.

The invention relates to a soapberry in-situ gel preparation for treating candida albicans vaginitis and a preparing method thereof, and belongs to the technical field of gynecological medication. Thepreparing method comprises the steps: preparing a water extraction fermentation concentrate of soapberry, preparing a water extract fermentation liquid with a proper concentration according to the saponin content, and preparing a temperature-sensitive gel from the water extract fermentation liquid, wherein the effective residence time in vagina is ensured. The soapberry in-situ gel preparation has the advantages of simple production, little toxic and side effects, and significant effect against candida albicans, and can avoid the potential drug resistance threat of azole antifungal agents, has wide soapberry sources and convenient material taking.

The invention discloses a traditional Chinese medicine paste for treating oral diseases and a preparation method thereof. Kinase 0.3-0.7 grams. The preparation method is as follows: the first step: peel the croton and watermelon seeds; the second step: make urokinase: precipitate the urine of healthy people for 48 hours, and extract the precipitate; the third step: the above-mentioned processed croton, Watermelon seeds, urokinase and silver vermilion are mixed evenly and crushed into a powder, the above weight of human milk is taken, the above powder is made into a paste, and the above paste is placed on a black cotton cloth to obtain the traditional Chinese medicine patch. The invention is a traditional Chinese medicine plaster for treating oral diseases caused by candida, such as tonsillitis, lymphadenitis and pharyngitis. The invention has the characteristics of remarkable curative effect, no toxic and side effects and avoiding the difficulty of taking medicine.

The invention discloses the use of 1-(4-hydroxy-3-methoxybenzene)--7-(4-hydroxyphenyl)-3,5-dihydroxy heptane in preparing medicament for resisting candida albicans, wherein the effective constituent is obtained from conventional galangal rhizome crude slices through separating methods.

The invention discloses a method for preparing R-6-methoxy-1-aminoindane through dynamic kinetic resolution. The method comprises the following steps: using 6-methoxy-1-aminoindane as a raw material, and under co-catalysis of a biological resolution catalyst, namely, candida rugosa lipase, and a racemization catalyst, namely, a non-crystal nickel catalyst KT-02, conducting transesterification reaction on 6-methoxy-1-aminoindane and an acyl donor, namely, (R)-(-)-alpha-acetylmandelic acid, to generate an R-6-methoxy-1-aminoindane acyl compound, and conducting acid hydrolysis and alkali ionization on the acyl compound to obtain R-6-methoxy-1-aminoindane, wherein the optical purity of the finished product is greater than 99%. The method has the characteristics that the operation is simple, the racemization catalyst is cheap and easy to obtain, the raw material utilization is complete, and the optical purity of the product is high. The method has great guidance and application values in preparation of R-6-methoxy-1-aminoindane.

The invention belongs to the field of biomedicines and in particular relates to a compound for preventing and controlling candida albicans as well as a preparation method and application thereof. Thecompound provided by the invention is 3-methyl-N-(2'-phenemyl)butyramide; an actinomyces streptomyces olivaceus SCSIO T05deltarsdK2/deltaxmcP mutant strain is constructed through in-frame deletion; amplified fermentation is carried out through a mutant strain fermentation tank, and bacterium collection and centrifuging are carried out; part of mycelia are subjected to ultrasonic extraction throughacetone and part of supernatant is extracted through butanone; extract is combined according to an HPLC (High Performance Liquid Chromatography) analysis result; the compound is obtained by separating through various column chromatography methods. Compared with the prior art, the compound provided by the invention has the beneficial effects that the technology disclosed by the invention successfully prepares and screens the compound 3-methyl-N-(2'-phenemyl)butyramide which has the effects of inhibiting the adhesion of the candida albicans, the mycelium shape transformation and the pathogenicity; meanwhile, the compound 3-methyl-N-(2'-phenemyl)butyramide has relatively small toxicity, does not influence the growth of the candida albicans and human cells and is hopeful to promote and propelthe development of treatment of novel anti-fungus medicines.